Header Logo

Connection

JOHN KIRKWOOD to Cell Line, Tumor

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Cell Line, Tumor.
JOHN KIRKWOOD
Connection Strength
0.868
Cell Line, Tumor
  1. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. Pigment Cell Melanoma Res. 2022 01; 35(1):66-77.
    View in: PubMed
    Score: 0.115
  2. Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.
    View in: PubMed
    Score: 0.106
  3. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017 Nov 15; 23(22):6888-6892.
    View in: PubMed
    Score: 0.087
  4. Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma. Cancer Immunol Immunother. 2008 Sep; 57(9):1315-21.
    View in: PubMed
    Score: 0.045
  5. NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
    View in: PubMed
    Score: 0.036
  6. LAG-3 and PD-1 synergize on CD8+ T?cells to drive T cell exhaustion and hinder autocrine IFN-?-dependent anti-tumor immunity. Cell. 2024 Aug 08; 187(16):4355-4372.e22.
    View in: PubMed
    Score: 0.035
  7. GZ17-6.02 kills PDX isolates of uveal melanoma. Oncotarget. 2024 May 17; 15:328-344.
    View in: PubMed
    Score: 0.035
  8. TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma. Science. 2022 Nov 11; 378(6620):664-668.
    View in: PubMed
    Score: 0.031
  9. Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines. SLAS Discov. 2021 06; 26(5):712-729.
    View in: PubMed
    Score: 0.027
  10. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020 07 17; 5(49).
    View in: PubMed
    Score: 0.027
  11. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Clin Cancer Res. 2020 10 15; 26(20):5520-5533.
    View in: PubMed
    Score: 0.027
  12. Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 2019 03 07; 4(5).
    View in: PubMed
    Score: 0.024
  13. An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell. 2019 01 14; 35(1):33-45.e6.
    View in: PubMed
    Score: 0.024
  14. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gaq and Ga11 and kill uveal melanoma cells. Cancer Biol Ther. 2019; 20(5):700-710.
    View in: PubMed
    Score: 0.024
  15. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. Cancer Biol Ther. 2018 02 01; 19(2):132-137.
    View in: PubMed
    Score: 0.022
  16. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. 2017 Mar 07; 8(10):16367-16386.
    View in: PubMed
    Score: 0.021
  17. Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Rep. 2016 Apr 05; 15(1):171-180.
    View in: PubMed
    Score: 0.020
  18. Transcriptional repression of IFN?1 by ATF2 confers melanoma resistance to therapy. Oncogene. 2015 Nov 12; 34(46):5739-48.
    View in: PubMed
    Score: 0.018
  19. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res. 2014 Jun; 24(3):207-18.
    View in: PubMed
    Score: 0.017
  20. PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014 Apr 15; 5(7):1926-41.
    View in: PubMed
    Score: 0.017
  21. Characterization of an early passage Merkel cell polyomavirus-positive Merkel cell carcinoma cell line, MS-1, and its growth in NOD scid gamma mice. J Virol Methods. 2013 Jan; 187(1):6-14.
    View in: PubMed
    Score: 0.016
  22. Mitochondrial respiration--an important therapeutic target in melanoma. PLoS One. 2012; 7(8):e40690.
    View in: PubMed
    Score: 0.015
  23. Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1. J Immunol. 2011 Jan 01; 186(1):312-22.
    View in: PubMed
    Score: 0.014
  24. A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res. 2009 Sep 15; 69(18):7459-65.
    View in: PubMed
    Score: 0.013
  25. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009 May 01; 182(9):5240-9.
    View in: PubMed
    Score: 0.012
  26. Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin Immunol. 2008 May; 127(2):123-9.
    View in: PubMed
    Score: 0.011
  27. A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6796-806.
    View in: PubMed
    Score: 0.011
  28. Expression analysis of genes identified by molecular profiling of VGP melanomas and MGP melanoma-positive lymph nodes. Cancer Biol Ther. 2004 Jan; 3(1):110-20.
    View in: PubMed
    Score: 0.009
  29. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. Cancer Res. 2003 Oct 01; 63(19):6506-15.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.